Search Results

MDx-Chex for BCP is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of Gram-positive bacteria and associated antimicrobial resistance genes, by the Diasorin LIAISON PLEX Gram-Positive Blood Culture assay on the LIAISON PLEX System. The MDx-Chex BCP Positive and Negative Controls are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Positive Control: Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium; genus: Bacillus spp., Listeria spp., Staphylococcus spp., Streptococcus spp.; antimicrobial resistance genes: mecA/mecC, vanA, and vanB. Negative Control: buffered solution only. This product is not intended to replace manufacturer controls provided with the device.

MDx-Chex® for BCP is a quality control kit consisting of two controls for the Diasorin LIAISON-PLEX Gram-Positive Blood Culture Assay (BCP). The MDx-Chex for BCP Positive Control is positive for pathogens and resistance mechanisms in the LIAISON-PLEX Gram-Positive Blood Culture assay (See Table 1). The MDx-Chex for BCP Negative Control is negative for pathogen and antimicrobial resistance genes in the LIAISON-PLEX Gram-Positive Blood Culture assay. Each control mix also contains and controls for blood and blood culture media components that have been identified as assay inhibitors, namely hemoglobin, leukocyte DNA, and anticoagulants.

MDx-Chex® for BCP is also configured as a verification kit (MDx-Chex® for BCP Verification Kit) for use at equipment installation, in the development of workflow procedures and for operator proficiency evaluation.

N/A

Ask a specific question about this device

MDx-Chex for BCN is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of Gram-negative bacteria and associated antimicrobial resistance genes, by the Diasorin LIAISON PLEX Gram-Negative Blood Culture assay on the LIAISON PLEX System. MDx-Chex for BCN Control 1 and Control 2 are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Control 1: Gram-negative bacteria: Acinetobacter baumannii, Haemophilus influenzae, Neisseria meningitidis, Pseudomonas aeruginosa, Stenotrophomonas maltophilia; genus: Acinetobacter spp., Pseudomonas spp.; antimicrobial resistance genes: KPC, NDM, and VIM. Control 2: Gram-negative bacteria: Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella variicola, Morganella morganii, Serratia marcescens; family/genus: Enterobacteriaceae/Morganellaceae, Citrobacter spp., Enterobacter spp., Proteus spp., Salmonella spp.; antimicrobial resistance genes: CTX-M, IMP, MCR, OXA, and SME. This product is not intended to replace manufacturer controls provided with the device.

MDx-Chex® for BCN is a quality control kit consisting of two controls for the Diasorin LIAISON-PLEX Gram-Negative Blood Culture Assay (BCN). The MDx-Chex for BCN Control 1 is positive for certain pathogens and resistance mechanisms in the LIAISON-PLEX Gram-Negative Blood Culture assay and negative for those contained in MDx-Chex for BCN Control 2. The MDx-Chex for BCN Control 2 is positive for the remaining pathogen and antimicrobial resistance genes in the LIAISON-PLEX Gram-Negative Blood Culture assay and negative for those present in MDx-Chex for BCN Control 1 (See Table 1). Each control mix also contains and controls for blood and blood culture media components that have been identified as assay inhibitors, namely hemoglobin, leukocyte DNA, and anticoagulants.

MDx-Chex for BCN is also configured as a verification kit (MDx-Chex for BCN Verification Kit) for use at equipment installation, in the development of workflow procedures and for operator proficiency evaluation.

N/A

Ask a specific question about this device

MDx-Chex for BCY is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of yeast by the Diasorin LIAISON PLEX Yeast Blood Culture assay on the LIAISON PLEX System. The MDx-Chex for BCY Positive and Negative Controls are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components.

Positive Control: Yeast: Candida albicans, Candida dubliniensis, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida auris, Candida kefyr, Candida lipolytica, Candida lusitaniae, Candida guilliermondii, Cryptococcus neoformans/gattii, Candida famata, Candida haemulonii/duobushamulonii.

Negative Control: buffered solution only.

This product is not intended to replace manufacturer controls provided with the device.

MDx-Chex for BCY is a quality control kit consisting of two controls for the Diasorin LIAISON-PLEX Yeast Blood Culture Assay (BCY). The MDx-Chex for BCY Positive Control is positive for pathogens in the LIAISON-PLEX Yeast Blood Culture assay (See Table 1). The MDx-Chex for BCY Negative Control is negative for pathogen in the LIAISON-PLEX Yeast Blood Culture assay. Each control mix also contains and controls for blood and blood culture media components that have been identified as assay inhibitors, namely hemoglobin, leukocyte DNA, and anticoagulants.

MDx-Chex for BCY is also configured as a verification kit (MDx-Chex for BCY Verification Kit) for use at equipment installation, in the development of workflow procedures and for operator proficiency evaluation.

N/A

Ask a specific question about this device

Multichem ID-G: Multichem ID-G is intended for use as a qualitative positive quality control serum to monitor the precision of laboratory testing procedures for Anti-HBc IgG, Anti-HCV IgG, HBsAg, Anti-Treponema pallidum IgG and Anti-HIV 1 IgG detected by Roche cobas heterogeneous immunoassay systems. These products are not intended to replace manufacturer's recommended controls provided in their package insert. Quality Control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

Multichem ID-GNeg: Multichem ID-GNeg is intended for use as a qualitative negative quality control serum to monitor the precision of laboratory testing procedures for Anti-HBc IgG, Anti-HCV IgG, HBsAg, Anti-Treponema pallidum IgG and Anti-HIV 1 IgG detected by the Roche cobas heterogeneous immunoassay systems. These products are not intended to replace manufacturer's recommended controls provided in their package insert. Quality Control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

Multichem ID-G and Multichem ID-GNeg are each supplied as single level controls. These products are prepared from human plasma. Multichem ID-G contains Hepatitis B Surface Antigen (HBsAg), and lgG antibodies to HIV-1 (Human Immunodeficiency Virus Type 1), HCV (Hepatitis C Virus), HBc (Hepatitis B Core Antigen) and Treponema pallidum. Multichem ID-GNeg does not contain analytes for HBsAg, anti-HIV-1 lgG, anti-HCV lgG, anti-HBc lgG, and anti-Treponema pallidum lgG. These controls are provided in liquid form for convenience. Each control is available as either 1 or 4 vials x 4 ml/vial.

Multichem ID-G is manufactured by adding the required analytes to the negative delipidated human serum base matrix, described above. Human disease state plasma that has tested positive for the required analyte using an FDA-cleared/approved assay is used to spike the base matrix to each target specification and within the ranges set for the Roche Immunoassay systems (Tables 1 and 2).

N/A

Ask a specific question about this device

The FilmArray GI Control Panel M238 is intended for use as an external positive and negative assayed quality control to monitor performance of the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel and the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid assays on the BIOFIRE FILMARRAY systems. BIOFIRE FILMARRAY Gastrointestinal (GI) Panel and the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid assays qualitatively detect the following targets: Campylobacter (C. jejuni/C. coli/C. upsaliensis), Clostridium (Clostridioides) difficile toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio (V. parahaemolyticus/V. vulnificus/V. cholerae), Yersinia enterocolitica, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC) lt/st, Shiga-like toxin-producing E. coli (STEC) stx1/stx2, E. coli O157, Shigella/Enteroinvasive E. coli (EIEC), Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia, Adenovirus F 40/41, Astrovirus, Norovirus GI/GII, Rotavirus A, and Sapovirus. The FilmArray GI Control Panel M238 contains synthetic RNA transcripts in stabilizing solution, buffers, and preservatives. The FilmArray GI Control Panel M238 is designed for and intended to be used solely with the BIOFIRE FILMARRAY GI Panel and the BIOFIRE FILMARRAY GI Panel Mid assays. This product is not intended to replace manufacturer internal controls provided with these devices.

FilmArray GI Control Panel M238, P/N M238, is a quality control panel consisting of 2 single use, ready-to-use, liquid controls, FilmArray GI Control M239, P/N M239, and FilmArray GI Control M240, P/N M240. Each kit of FilmArray GI Control Panel M238 is comprised of 6 tubes of M239 and 6 tubes of M240. Together the 2 controls contain synthetic RNA corresponding to genome segments of all the pathogens detected by the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel and BIOFIRE FILMARRAY GI Panel Mid assays, suspended in a non-infectious solution of buffers, preservatives and stabilizers.

Each liquid control of FilmArray GI Control Panel M238 is processed separately according to the BIOFIRE GI Panel and BIOFIRE GI Panel Mid manufacturer's Instructions for Use for patient samples, stool samples in Cary Blair transport media obtained from individuals with signs and/or symptoms of gastrointestinal infection.

The provided FDA 510(k) clearance letter and summary discuss the validation of the FilmArray GI Control Panel M238. This device is an assayed quality control material, not an AI/ML-driven diagnostic device. Therefore, many of the requested elements the prompt is asking for (e.g., number of experts, adjudication methods, MRMC study, training sets, human-in-the-loop performance) are not applicable to this type of device.

However, I can extract and present the relevant information regarding its acceptance criteria and the study that proves it meets those criteria, focusing on the concepts applicable to quality control materials:

Device: FilmArray® GI Control Panel M238 (M238)

This device is an external positive and negative assayed quality control used to monitor the performance of the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel and the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid assays. It contains synthetic RNA transcripts as targets.

Acceptance Criteria and Reported Device Performance

The core acceptance criterion for a quality control material like this is its ability to consistently produce the correct expected results (either positive or negative depending on the specific control) when tested with the target assay. The study demonstrated 100% correctness across all valid tests.

Table 1: Acceptance Criteria and Reported Device Performance

Study Details Proving Acceptance Criteria are Met

1. Sample Size Used for the Test Set and Data Provenance:
* Sample Size: A total of 165 samples were tested.
* 79 samples of FilmArray GI Control M239 (positive control)
* 86 samples of FilmArray GI Control M240 (negative control)
* Data Provenance: The device was manufactured at MMQCI's facility in Saco, Maine, and tested at 2 unspecified sites. The study was prospective in nature, as it involved the creation and testing of new control lots specifically for this submission. The country of origin of the data is implicitly the USA, given the FDA filing and US company address.

2. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
* Not applicable in the conventional sense for a quality control material. The "ground truth" for a quality control material is its pre-defined composition, meaning it is designed to contain specific targets (for the positive control) or no targets (for the negative control). The BIOFIRE FILMARRAY GI Panel itself serves as the reference against which the control material's behavior is assessed.
* The study involved 9 operators, who presumably were trained laboratory personnel using the BIOFIRE FILMARRAY system according to its Instructions for Use. Their role was in executing the tests, not in establishing a medical "ground truth" through expert review as would be the case for image-based diagnostic AI.

3. Adjudication Method for the Test Set:
* Not applicable. The results are qualitative (Positive/Negative for specific targets, or Valid/Invalid run) and are determined by the automated output of the BIOFIRE FILMARRAY system. There is no subjective interpretation requiring adjudication among experts. The "adjudication" is purely objective: did the control material yield the expected automated result on the instrument?

4. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:
* No. MRMC studies are typically performed for diagnostic imaging devices where human readers interpret patient cases. This device is a quality control material for an in vitro diagnostic (IVD) assay, not a diagnostic imaging device, nor does it involve human interpretation of complex medical cases. The study demonstrated the device's ability to monitor the performance of the BIOFIRE FILMARRAY system itself.

5. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:
* This question is more relevant to AI/ML software. In the context of this quality control material, its "standalone" performance refers to its ability to elicit the expected results from the BIOFIRE FILMARRAY system independently. The study demonstrates this functional performance, showing 100% correct results triggered by the control material when used with the instrument, which is the equivalent of "standalone" functionality for this type of product.

6. The Type of Ground Truth Used:
* Defined Composition: For quality control materials, the ground truth is the known, pre-defined composition of the control panel itself. The M239 control is designed to be positive for certain targets, and the M240 control is designed to be negative or non-reactive. The "correctness" is therefore a measure of whether the BIOFIRE FILMARRAY system, when challenged with these known controls, reports the expected results.

7. The Sample Size for the Training Set:
* Not applicable. This is a quality control material, not an AI/ML algorithm that requires a training set. The "training" for such a product implicitly involves its manufacturing and formulation process to achieve the desired composition and stability.

8. How the Ground Truth for the Training Set was Established:
* Not applicable, as there is no training set in the context of an AI/ML algorithm. For the manufacturing of the quality control material, the "ground truth" is established by the precise formulation and characterization of the synthetic RNA transcripts and other components to ensure the desired positive or negative reactivity.

Ask a specific question about this device

The SPOTFIRE® RSP Pos & Neg Controls kit is intended for use (as an external positive and negative assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae, Streptococcus dysgalactiae (Group C/G Strep), Streptococcus pyogenes (Group A Strep), Adenovirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini on the BIOFIRE System. SPOTFIRE RSP Pos & Neg Controls is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mimi, BIOFIRE SPOTFIRE R/ST Panel, and BIOFIRE SPOTFIRE R/ST Panel Mini assays. The SPOTFIRE RSP Positive Control contains synthetic RNA transcripts in stabilizing solution, and the SPOTFIRE RSP Negative Control contains buffers and preservatives. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

SPOTFIRE® RSP Negative Control is intended for use (as applicable) as an external negative assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Bordetella parapertussis. Bordetella pertussis. Chlamydia pneumoniae. Streptococcus dysgalactiae (Group C/G Strep), Streptococcus pyogenes (Group A Strep), Adenovirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini on the BIOFIRE System. SPOTFIRE RSP Negative Control is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, BIOFIRE SPOTFIRE R/ST Panel, and BIOFIRE SPOTFIRE R/ST Panel Mini assays. SPOTFIRE RSP Negative Control is comprised of a solution of buffer and preservatives that does not contain target analytes. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

SPOTFIRE RSP Pos & Neg Controls, P/N M425, is a quality control panel consisting of 12 readyto-use, liquid controls, 6 of SPOTFIRE RSP Positive Control (Positive Control), P/N M42638, and 6 of SPOTFIRE RSP Negative Control (Negative Control), P/N M42738, in a single kit box, and a separate kit of 6 additional SPOTFIRE RSP Negative Controls (Negative Control), P/N M42738. The separate kit of SPOTFIRE RSP Negative Control allows and encourages the end user to check for environmental contamination by testing additional negative controls. The Positive Control contains non-infectious surrogate control material; a solution of synthetic RNA transcripts in buffer, stabilizers and preservatives. The RNA in the Positive Control carries RNA segments of all the respiratory and sore throat pathogens detected by the BIOFIRE SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini assays. performed on the BIOFIRE System. SPOTFIRE RSP Pos & Neg Controls are specifically designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, BIOFIRE SPOTFIRE R/ST Panel, and BIOFIRE SPOTFIRE R/ST Panel Mini assays on the BIOFIRE SPOTFIRE System. The Negative Control contains buffer and preservatives with no RNA. Each liquid control of SPOTFIRE RSP Pos & Neg Controls is processed separately according to the SPOTFIRE Panel assay manufacturer's Instructions for Use for patient samples (nasopharyngeal swabs or throat swabs placed in transport media) obtained from individuals with signs and symptoms of respiratory tract infection or pharyngitis. Engineering drawings, schematics, etc. are not applicable to the device (device is a reagent).

The provided text is a 510(k) premarket notification for a medical device called "SPOTFIRE® RSP Pos & Neg Controls." This document focuses on the regulatory aspects of changing an existing, cleared device (K233611) rather than presenting a detailed study proving performance against specific acceptance criteria for a new device.

Therefore, I cannot extract the information required to populate a table of acceptance criteria and reported device performance from this document, nor can I describe a study that proves the device meets specific acceptance criteria in the context of an AI/ML-driven medical device, as the device in question is an assayed quality control material for clinical microbiology assays, not an AI/ML diagnostic tool.

The document states:

• "Performance data presented in the predicate 510(k) submission (K233611) has all the required data to support the labeling change to the existing device to include the SPOTFIRE R/ST Panel Mini in the intended use for SPOTFIRE RSP Pos & Neg Controls, and the packaging change to combine Positive and Negative controls in a single kit box. No additional performance data are required as the SPOTFIRE RSP Pos & Neg Controls have not been changed, the assay consumables are identical for the SPOTFIRE R/ST Panel used to collect original performance data and the SPOTFIRE R Panel Mini. In addition, the targets reported in the SPOTFIRE R/ST Panel Mini are a subset of the SPOTFIRE R/ST Panel."

This explicitly states that no new performance study was conducted for this specific submission (K241289) because the changes were considered minor (labeling and packaging, and the new panel is a subset of an already cleared panel). The previous 510(k) (K233611) would contain the original performance data, but that information is not provided in this document.

As a result, I cannot provide details on:

1. A table of acceptance criteria and the reported device performance: Not present, as no new performance study was conducted.
2. Sample size used for the test set and data provenance: Not present.
3. Number of experts used to establish ground truth and qualifications: Not applicable/present.
4. Adjudication method for the test set: Not applicable/present.
5. Multi Reader Multi Case (MRMC) comparative effectiveness study: Not applicable, as this is a quality control material, not an AI diagnostic tool involving human readers.
6. Standalone (algorithm only) performance: Not applicable.
7. Type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not applicable/present in this document.
8. Sample size for the training set: Not applicable (not an AI/ML device, and no new training/testing).
9. How the ground truth for the training set was established: Not applicable.

The document's purpose is to demonstrate substantial equivalence to an existing predicate device based on minor changes, not to present novel performance data for a new device.

Ask a specific question about this device

SPOTFIRE® RSP Positive Control is intended for use (as applicable) as an external positive assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae, Streptococcus dysgalactiae (Group C/G Strep), Streptococcus pyogenes (Group A Strep), Adenovirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mimi, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE SPOTFIRE System. SPOTFIRE RSP Positive Control is comprised of in vitro RNA transcripts and stabilizing solution and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

SPOTFIRE® RSP Negative Control is intended for use (as applicable) as an external negative assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Streptococcus dysgalactiae (Group C/G Strep), Streptococcus pyogenes (Group A Strep), Adenovirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE System. SPOTFIRE RSP Negative Control is comprised of a solution that does not contain target and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

SPOTFIRE RSP Pos & Neg Controls, P/N M425, is a quality control panel consisting of 2 readyto-use, liquid controls, SPOTFIRE RSP Positive Control (Positive Control), P/N M42638 and SPOTFIRE RSP Negative Control (Negative Control), P/N M42738. The Positive Control contains non-infectious surrogate control material; a solution of synthetic RNA transcripts in buffer, stabilizers and preservatives. The RNA in the Positive Control carries RNA segments of all the respiratory and sore throat pathogens detected by the BIOFIRE SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel assays, performed on the BIOFIRE System. The Negative Control contains buffer and preservatives with no RNA. Each liquid control of SPOTFIRE RSP Pos & Neg Controls is processed separately according to the SPOTFIRE Panel assay manufacturer's Instructions for Use for patient samples (nasopharyngeal swabs or throat swabs placed in transport media) obtained from individuals with signs and symptoms of respiratory tract infection or pharyngitis.

The provided text is a 510(k) Summary for a medical device called "SPOTFIRE RSP Pos & Neg Controls," which are quality control materials for molecular diagnostic assays. The submission is a change to an existing device (K230868) to include compatibility with a new panel, the "BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel."

The document details the device's intended use, its description, and a summary of performance data collected to demonstrate that the modified device remains substantially equivalent to its predicate.

Here's the breakdown of the acceptance criteria and study information, as requested:

Acceptance Criteria and Reported Device Performance

Study Information

1. Sample Size Used for the Test Set and Data Provenance:

   • Total Test Results: 361 initially, with 10 invalid results that were repeated, leading to 351 valid test results used for performance analysis.
   • Data Provenance:
     • External Study: 232 test results collected from 5 near-patient clinical sites. The document does not specify the country of origin of these sites, but given the FDA submission, it's presumed to be in the USA. This was a prospective study as the sites were asked to follow specific protocols for testing controls during normal operations (e.g., training new operators, new kit shipments, new/repaired instruments).
     • Internal Study: 129 test results collected from MMQCI's facility in Saco, Maine (USA). This was also a prospective study.

2. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts:

   • This study evaluates the performance of quality control materials for in vitro laboratory nucleic acid testing. The "ground truth" here is objective: either the control produced the expected positive result (detecting the specified analytes) or the expected negative result (no target analytes detected).
   • Therefore, no human experts (like radiologists) were establishing a subjective "ground truth" diagnosis. The performance is based on whether the automated instrument correctly identifies the presence or absence of the target analytes in the control material as designed.

3. Adjudication Method for the Test Set:

   • Not applicable in the conventional sense of human expert discrepancies. The performance is measured against the pre-defined composition of the positive and negative control materials.
   • Invalid results (instrument errors, failed internal pouch controls) were re-tested according to BioFire instructions and excluded from the "Percent Correct" analysis. This acts as a form of "adjudication" for technical failures rather than diagnostic disagreement.

4. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:

   • No, an MRMC comparative effectiveness study was not done. This study is not evaluating a diagnostic AI algorithm that assists human readers. It's evaluating the performance of quality control materials for a molecular diagnostic assay. The "users" are laboratory professionals (or non-lab professionals in CLIA waived settings) operating the BIOFIRE SPOTFIRE System. The study assessed the reproducibility of the control materials, not the improvement of human readers with AI assistance.

5. If a Standalone (algorithm only without human-in-the-loop performance) was done:

   • This is not an AI algorithm. The performance evaluation is inherently "standalone" in the sense that the control materials are processed by the BIOFIRE SPOTFIRE System, and the system's output (positive or negative detection of specific analytes) is compared against the known composition of the control. The "human-in-the-loop" would be the technician performing the test, but their role is to follow instructions, not to interpret complex images or data subjectively.

6. The Type of Ground Truth Used:

   • The ground truth is the known, manufactured composition of the control materials.
     • Positive Control: Contains synthetic RNA transcripts for all target respiratory and sore throat pathogens. The ground truth is that these specific targets should be detected by the assay.
     • Negative Control: Contains buffer and preservatives with no RNA targets. The ground truth is that no target analytes should be detected.

7. The Sample Size for the Training Set:

   • Not applicable. This device is a quality control material, not a machine learning or AI model. Therefore, there is no "training set" in the context of algorithm development. The control materials are manufactured to a specific design.

8. How the Ground Truth for the Training Set was Established:

   • Not applicable, as there is no training set for an AI/ML model. The ground truth for the control materials is inherent in their design and manufacturing process.

Ask a specific question about this device

The HAVAb IgG II assay is a chemiluminescent microparticle immunoassay (CMA) used for the qualitative detection of IgG antibody to hepatitis A virus (IgG anti-HAV) in human adult and pediatric (4 through 21 years) serum (collected in serum and serum separator tubes) and plasma (collected in sodium heparin, lithium heparin separator, dipotassium EDTA, and tripotassium EDTA tubes) from patients with signs and symptoms or at risk for hepatitis A on the Alinity i system.

The HAVAb IgG II assay is used to determine the immune status of individuals to hepatitis A virus (HAV) infection. Warning: This assay has not been cleared for use in screening blood, plasma, or tissue donors. This assay camot be used for the diagnosis of acute HAV infection.

Assay performance characteristics have not been established when the HAVAb IgG II assay is used in conjunction with other hepatitis assays.

The HAVAb IgG II assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG antibody to hepatitis A virus (IgG anti-HAV) in human adult and pediatric (4 through 21 years) serum (collected in serum and serum separator tubes) and plasma (collected in sodium heparin, lithium heparin separator, dipotassium EDTA, and tripotassium EDTA tubes) from patients with signs and symptoms or at risk for hepatitis A on the Alinity i system. The kit includes reagents (Microparticles, Conjugate, Assay Diluent), Calibrator, and Controls. The assay is an automated, two-step immunoassay.

Considering the provided document, the device described is an in vitro diagnostic (IVD) assay (HAVAb IgG II) for the qualitative detection of IgG antibody to hepatitis A virus (IgG anti-HAV). The FDA 510(k) summary focuses on establishing substantial equivalence to a predicate device, not on meeting specific acceptance criteria in the context of an AI/ML medical device's performance evaluation against clinical ground truth.

Therefore, many of the requested criteria (like ground truth establishment by experts, adjudication methods, multi-reader multi-case studies, and separate training/test sets with their ground truth establishment) are generally not applicable to the performance claims made for this in vitro diagnostic device in this FDA submission. The document describes analytical and clinical performance studies typical for an IVD, focusing on agreement with a predicate device and reproducibility/precision, rather than predictive performance of an AI model against a complex clinical endpoint established by human experts.

Based on the provided text, here's a breakdown of the information that is applicable and a clear indication where the requested information is not present or relevant to this type of device submission:

1. A table of acceptance criteria and the reported device performance

The document doesn't explicitly state "acceptance criteria" in a table format that would typically be found for an AI/ML model for diagnostic imaging (e.g., target sensitivity/specificity values). Instead, it presents performance data for comparison to a predicate device and for reproducibility. The implicit "acceptance criterion" for a 510(k) is demonstrating "substantial equivalence" to a legally marketed predicate device.

However, we can infer some performance metrics presented as evidence of equivalence:

2. Sample sizes used for the test set and the data provenance

• Clinical Performance Test Set (Agreement with Predicate):

  • Individuals at Increased Risk of HAV Infection: n=250
  • Individuals with Signs and Symptoms of Hepatitis Infection: n=499
  • Pediatric Population: n=105
  • Total for Agreement Study: 250 + 499 + 105 = 854 specimens.
  • Data Provenance: Prospective multi-center study.
    • Increased Risk of HAV: collected in California, Colorado, Florida, Illinois, Massachusetts, North Carolina, and Texas.
    • Signs and Symptoms of Hepatitis: collected in California, Colorado, Florida, Illinois, Massachusetts, and Texas.
    • Pediatric Population: collected in the US (California and Massachusetts) and Belgium.

• Precision/Reproducibility Test Sets:

  • Within-Laboratory Precision: n=80 per sample/control for a representative combination (tested over 20 days, 2 replicates/day). Total tested for this study was 4 reagent/calibrator/instrument combinations.
  • System Reproducibility: n=360 per sample/control (tested at 3 sites, with 4 replicates/run, 2 runs/day, 5 days).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

• Not applicable / Not stated. For this IVD device, the "ground truth" for the clinical performance study was the result produced by the legally marketed predicate device (ARCHITECT HAVAB-G). This is a common practice for 510(k) submissions for IVDs. There were no human experts adjudicating results for the purpose of establishing a "ground truth" beyond what the predicate device determined.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

• Not applicable. As the ground truth was the predicate device's result, no human adjudication method (like 2+1, 3+1) was used or described.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• Not applicable. This is an in vitro diagnostic assay, not an imaging AI device intended to assist human readers. Therefore, an MRMC study and evaluation of human reader improvement with AI assistance were not performed.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Yes, in spirit. The device (HAVAb IgG II assay) functions as a standalone test; it's an automated immunoassay that generates a qualitative result (Reactive or Nonreactive) without human interpretation in the loop influencing the output beyond sample collection and instrument operation. Its performance was assessed directly against the predicate device's results.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

• The "ground truth" for the clinical performance comparison was the results from a legally marketed predicate device (ARCHITECT HAVAB-G assay). In essence, the performance of the new device was compared to the established performance of the predicate. This is a common form of "truth" in demonstrating substantial equivalence for IVDs.

8. The sample size for the training set

• Not explicitly stated in terms of a "training set" for model development. This is an immunoassay, not an AI/ML model where a distinct training dataset size is typically reported. The document describes analytical verification and clinical performance studies, not model training.

9. How the ground truth for the training set was established

• Not applicable. As this is not an AI/ML device in the sense of a machine learning model requiring a training set with a ground truth established by experts for supervised learning, this information is not provided. The development process for an immunoassay does not involve "training data" in the same way an AI/ML model does.

Ask a specific question about this device

MDx-Chex™ for BC-GP is intended for use as an external positive assayed control to monitor the performance of the qualitative detection of Gram-positive bacteria and associated antimicrobial resistance genes, by the Luminex VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on Luminex VERIGENE® systems. The MDx-Chex™ for BC-GP Positive and Negative Controls are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Positive bacteria: Staphylococcus aureus, Staphylococus epidermidis, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococus pyogenes, Enterococcus faecium, Streptococus faecium, Streptococus anginosus group; Species: Staphylococcus spp., Streptococcus spp.; antimicrobial resistance genes: mecA, vanA and vanB. Negative Control: buffered solution only. This product is not intended to replace manufacturer controls provided with the device.

MDx-Chex™ for BC-GP is a quality control kit consisting of positive and negative controls for the Luminex VERIGENE® Gram-Positive Blood Culture Test (BC-GP). The MDx-Chex™ for BC-GP Positive Control is positive for pathogens and resistance mechanisms in the VERIGENE BC-GP test (See Table 1). The MDx-Chex™ for BC-GP Negative Control is negative for pathogens and resistance mechanisms in the VERIGENE BC-GP test. Each control mix also controls for blood and blood culture media components that have been identified is inhibitors to DNA hybridization assays, namely hemoglobin, leukocyte DNA, and anticoagulants.

The MDx-Chex™ for BC-GP quality control kit contains stabilized blood components, blood culture media components, and inactivated, intact microorganisms resulting in a full-process, cellular-based control for the Luminex VERIGENE BC-GP panel.

Here's a breakdown of the acceptance criteria and the study used to prove the device meets these criteria, based on the provided text:

Device: MDx-Chex™ for BC-GP (Assayed Quality Control Material For Clinical Microbiology Assays)

Intended Use: To monitor the performance of qualitative detection of Gram-positive bacteria and associated antimicrobial resistance genes by the Luminex VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on Luminex VERIGENE® systems.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criterion for all performance studies is ≥ 90% agreement with expected results.

2. Sample Size Used for the Test Set and Data Provenance

• Multi-Site Precision (Reproducibility):
  • Sample Size: 30 positive control samples and 30 negative control samples per lot (for each site, making a total of 90 positive and 90 negative samples across 3 sites for 1 lot, and 180 total runs per control type for all lots). The study used 3 lots, so effectively 30 positive and 30 negative tests per lot across 3 sites.
  • Provenanc: Not explicitly stated, but implies a prospective study conducted at 3 different sites as part of device validation.
• Single-Site Precision (Repeatability):
  • Sample Size: 20 samples per control type (positive and negative control tubes), 40 samples per MDx-Chex™ for BC-GP lot. Across 3 lots, this accumulated to 120 runs (20 runs per control type per lot across 3 lots).
  • Provenance: Not explicitly stated, but implies a prospective study conducted at a single site as part of device validation.
• Lot-to-Lot Reproducibility:
  • Sample Size: For the Lot-to-lot study, data from 10 positive and 10 negative control tubes per lot (30 data points per control type across 3 lots, totaling 60 data points). For the within-run precision, 10 tests for each positive and negative control tube from one lot (total of 20 tests).
  • Provenance: Not explicitly stated, but implies a prospective study.
• Closed-Vial Stability and Shipping Stability:
  • Sample Size: 20 positive and 20 negative control samples per MDx-Chex lot, collected at different data collection timepoints and stored at room (25°C) and refrigerated (2°C) temperatures. With 3 lots, this amounts to 60 positive and 60 negative total samples tested for each storage condition and time point. For shipping stability, one lot with 20 samples per control type for each simulated shipping profile.
  • Provenance: Not explicitly stated, but implies a prospective study.
• Matrix Effect:
  • Sample Size: Simulated positive MDx-Chex™ for BC-GP matrix and simulated positive clinical sample were tested in triplicate (3 samples each). Similarly, non-spiked simulated samples (negative controls) were tested in triplicate.
  • Provenance: Not explicitly stated, but implies a prospective study.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This device is an assayed quality control material for in vitro diagnostic tests. The ground truth (i.e., whether a control is 'positive' or 'negative' for specific pathogens/resistance genes) is inherent to the control material's design and formulation, not established by human experts interpreting results. The controls contain "inactivated, intact microorganisms" and specific resistance genes, and are designed to elicit a known positive or negative result on the target diagnostic system.

4. Adjudication Method for the Test Set

Adjudication methods like "2+1" or "3+1" are typically used for studies where human interpretation or consensus is required to establish ground truth (e.g., image interpretation). For an in vitro diagnostic quality control material like MDx-Chex™ for BC-GP, the "ground truth" of what the control should detect is pre-defined by its composition. There is no human adjudication process described or expected. The results from the Luminex VERIGENE® system are compared directly to the expected outcome of the quality control material.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices that involve human interpretation (e.g., radiologists reading images) and assessing how AI assistance might improve human performance. MDx-Chex™ for BC-GP is a quality control material for an automated molecular diagnostic test (Luminex VERIGENE® BC-GP) and does not involve human interpretation in the same way. The studies focus on the performance and stability of the control material itself.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, implicitly, the studies evaluate the "standalone" performance of the MDx-Chex™ controls when processed by the Luminex VERIGENE® System. Since the device is a quality control material, its "performance" is its ability to consistently produce the expected positive or negative results on the target instrument. The data presented demonstrates the consistency of these expected results. There's no "human-in-the-loop" component for the performance of the control material, other than operators performing the assay.

7. The Type of Ground Truth Used

The ground truth is pre-defined by the engineered composition of the quality control material.

• For the Positive Control, the ground truth is "Detected" for specific Gram-positive bacteria (e.g., Staphylococcus aureus, Enterococcus faecalis, Streptococcus pneumoniae) and antimicrobial resistance genes (mecA, vanA, vanB) that are intentionally included in the control.
• For the Negative Control, the ground truth is "Not Detected" because it is a buffered solution only, without the target microorganisms or resistance genes.

8. The Sample Size for the Training Set

Not applicable. This device is a quality control material, not an AI/machine learning algorithm that requires a training set. Its purpose is to monitor the performance of another diagnostic assay (Luminex VERIGENE® BC-GP), not to make diagnostic predictions itself.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for this device.

Ask a specific question about this device

MDx-Chex™ for BC-GN is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of Gram-Negative bacteria and associated antimicrobial resistance genes, by the Luminex VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) on Luminex VERIGENE® systems. The MDx-Chex™ for BC-GN Positive and Negative Controls are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Positive Control: Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Species: Acinetobacter spe., Citrobacter spp., Enterobacter spp., Proteus spp.; antimicrobial resistance genes: CTX-M, IMP, KPC, NDM, OXA and VIM. Negative Control: buffered solution only. This product is not intended to replace manufacturer controls provided with the device.

MDx-Chex™ for BC-GN is a quality control kit consisting of positive and negative controls for the Luminex VERIGENE® Gram-Negative Blood Culture Test (BC-GN). The MDx-Chex™ for BC-GN Positive Control is positive for pathogens and resistance mechanisms in the VERIGENE BC-GN test (See Table 1). The MDx-Chex™ for BC-GN Negative Control is negative for pathogens and resistance mechanisms in the VERIGENE BC-GN test. Each control mix also controls for blood and blood culture media components that have been identified is inhibitors to DNA hybridization assays, namely hemoglobin, leukocyte DNA, and anticoagulants.

The MDx-Chex™ for BC-GN quality control kit contains stabilized blood components, blood culture media components, and inactivated, intact microorganisms resulting in a full-process, cellular-based control for the Luminex VERIGENE BC-GN panel. Use of full-process cellular controls are necessary to evaluate the entire analytical process, including sample lysis, nucleic acid isolation, DNA hybridization detection, and analysis, as well as the impact of inhibitors present in blood culture samples and preanalytical variables. Routine use of full process quality controls can help identify variations in the test system that can lead to incorrect results.

The provided document describes the performance of the MDx-Chex™ for BC-GN device, a quality control material, rather than an AI/ML medical device for diagnosis or prediction. Therefore, many of the requested categories (e.g., number of experts, adjudication method, MRMC comparative effectiveness, standalone performance, training set details) are not applicable to this type of device and study.

However, I can extract the acceptance criteria and reported device performance from the provided text for the relevant studies.

Acceptance Criteria and Device Performance

The general acceptance criterion for all studies (Multi-Site Precision, Single-Site Precision, Lot-to-Lot Reproducibility, Closed-Vial Stability, and Shipping Stability) was ≥ 90% agreement with expected results. For Matrix Effect studies, the acceptance criteria was also ≥ 90% agreement for positive detection of analyte for positive controls and ≥ 90% agreement for negative detection of analyte for negative controls.

1. Table of Acceptance Criteria and the Reported Device Performance

2. Sample sizes used for the test set and the data provenance

• Multi-Site Precision:

  • Sample Size: 10 positive control samples and 10 negative control samples for each of 3 MDx-Chex™ for BC-GN lots, tested across 3 sites, for a total of 30 samples per control type per lot. This resulted in 90 runs per control type (positive/negative) and 180 total runs for data analysis.
  • Data Provenance: Not explicitly stated, but implies a prospective study design conducted by the manufacturer (Streck) for regulatory submission.

• Single-Site Precision (Repeatability):

  • Sample Size: 20 samples per control type (positive and negative) for each of 3 MDx-Chex™ for BC-GN lots, tested over 20 days. This resulted in 120 runs (20 runs per control type per lot) for data analysis.
  • Data Provenance: Not explicitly stated, but implies a prospective study design conducted by the manufacturer (Streck).

• Lot-to-Lot Reproducibility:

  • Sample Size: 10 positive and 10 negative control tubes per MDx-Chex™ for BC-GN lot (3 lots), resulting in 30 data points per control type (60 total data points).
  • Data Provenance: Not explicitly stated, but implies a prospective study design conducted by the manufacturer (Streck).

• Within-Run Precision:

  • Sample Size: 10 tests for each positive and negative control tube from one MDx-Chex™ for BC-GN lot (total of 20 tests).
  • Data Provenance: This data was sourced from the Day 60 (2C) closed-vial stability data.

• Closed-Vial Stability and Shipping Stability:

  • Sample Size: 20 positive and 20 negative control samples per MDx-Chex™ for BC-GN lot (3 lots), collected at different timepoints and stored at different temperatures. For shipping: one lot (RPL #22355) with 20 samples per control type for each simulated shipping profile.
  • Data Provenance: Not explicitly stated, but implies a prospective study design conducted by the manufacturer (Streck).

• Matrix Effect:

  • Sample Size: Simulated positive MDx-Chex™ for BC-GN matrix (triplicate), simulated positive clinical sample (triplicate), simulated negative MDx-Chex™ for BC-GN matrix (triplicate), simulated negative clinical sample (triplicate). Total of 12 tests.
  • Data Provenance: Not explicitly stated, but implies a prospective study design conducted by the manufacturer (Streck).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. This device is a quality control material for an in vitro diagnostic test. The "ground truth" is defined by the expected performance of the control material (i.e., whether it should be detected as positive or negative for specific pathogens/genes by the Luminex VERIGENE® BC-GN system). This "ground truth" is inherent to the control material's formulation and its intended reactivity with the target diagnostic system, not established by human experts.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. As a quality control material, the "ground truth" is binary (positive/negative for specific targets) and is determined by the composition of the control and the design of the diagnostic test it monitors. There is no human adjudication process involved.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is not an AI/ML diagnostic device, nor does it involve human readers or cases. It is a quality control material for an automated molecular diagnostic test.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The performance detailed is that of the quality control material when used "standalone" with the Luminex VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) on Luminex VERIGENE® systems. The "algorithm" in this context refers to the Luminex VERIGENE® system itself, and the studies assess how well the control material performs within that system as expected. The control itself does not have an "algorithm."

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The "ground truth" for these studies is the expected reactivity of the quality control material with the Luminex VERIGENE® BC-GN system.

• Positive Controls: Expected to be "Detected" for specific Gram-negative bacteria and antimicrobial resistance genes.
• Negative Controls: Expected to be "Not Detected" (buffered solution only).
  This ground truth is based on the known composition of the MDx-Chex™ for BC-GN control material.

8. The sample size for the training set

Not applicable. This device is a quality control material, not an AI/ML model that requires training data.

9. How the ground truth for the training set was established

Not applicable. See point 8.

Ask a specific question about this device